SCHEMBL18249758

SCHEMBL18249758

N#Cc1cc(Oc2ccc(CS(N)(=O)=O)cc2)nc(Cl)n1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DGAT2 Q96PD7 1/20 0.41
KDM4E B2RXH2 1/20 0.41
SMN1; SMN2 Q16637 4/20 0.40
ALDH1A1 P00352 5/20 0.39
RAB9A P51151 2/20 0.39
MEN1 O00255 2/20 0.36
KMT2A Q03164 2/20 0.36
CA1 P00915 2/20 0.34
CA2 P00918 2/20 0.34
CA9 Q16790 2/20 0.34
MAPT P10636 2/20 0.34
CA7 P43166 1/20 0.34
CA14 Q9ULX7 1/20 0.34
HPGD P15428 1/20 0.34
CA5A P35218 1/20 0.34
P2RX3 P56373 5/20 0.33
LMNA P02545 2/20 0.33
NPC1 O15118 1/20 0.33
ADRB2 P07550 1/20 0.33
TDP1 Q9NUW8 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18249752 0.85 SMN1; SMN2 (0.51) DGAT2SMN1; SMN2ALDH1A1RAB9AMEN1
SCHEMBL16738664 0.85 PDE2A (0.41) DGAT2KDM4ESMN1; SMN2ALDH1A1RAB9A
SCHEMBL20239187 0.82 LMNA (0.41) DGAT2KDM4ESMN1; SMN2ALDH1A1RAB9A
SCHEMBL20239277 0.81 GRM5 (0.45) DGAT2KDM4ESMN1; SMN2ALDH1A1RAB9A
SCHEMBL20239253 0.78 ALDH1A1 (0.43) KDM4ESMN1; SMN2ALDH1A1RAB9ACA1
SCHEMBL20239202 0.77 LMNA (0.54) DGAT2KDM4ESMN1; SMN2ALDH1A1MEN1
SCHEMBL20239281 0.77 DGAT2 (0.61) DGAT2KDM4ESMN1; SMN2ALDH1A1MEN1
SCHEMBL16882160 0.75 SMN1; SMN2 (0.52) DGAT2SMN1; SMN2ALDH1A1RAB9AMEN1
SCHEMBL20239355 0.74 DGAT2 (0.48) DGAT2KDM4ESMN1; SMN2ALDH1A1MEN1
SCHEMBL20239263 0.73 P2RX3 (0.44) DGAT2CA1CA2CA9P2RX3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-107635975-B DGAT2 inhibitors 伊莱利利公司 2020-07-24 CN disclosed
EP-3298001-B1 DGAT2 INHIBITORS LILLY CO ELI (US) 2020-05-13 EP disclosed
US-10053429-B2 DGAT2 inhibitors ELI LILLY AND COMPANY (US) 2018-08-21 US disclosed
US-20180162825-A1 NOVEL DGAT2 INHIBITORS ELI LILY AND COMPANY (US) 2018-06-14 US disclosed
US-20180162825-A1 NOVEL DGAT2 INHIBITORS ELI LILY AND COMPANY (US) 2018-06-14 US disclosed
US-20180162825-A1 NOVEL DGAT2 INHIBITORS ELI LILY AND COMPANY (US) 2018-06-14 US disclosed
EP-3298001-A1 NOVEL DGAT2 INHIBITORS Eli Lilly and Company (US) 2018-03-28 EP disclosed
WO-2016187384-A1 NOVEL DGAT2 INHIBITORS ELI LILLY AND COMPANY (US) 2016-11-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180162825-A1 NOVEL DGAT2 INHIBITORS DGAT2, DGAT1, LCAT DGAT2 1/4885KDM4E 4070/4885SMN1; SMN2 4828/4885
US-10053429-B2 DGAT2 inhibitors DGAT2, DGAT1, LCAT DGAT2 1/4885KDM4E 3891/4885SMN1; SMN2 4835/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.